BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 32721816)

  • 1. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis.
    Wang BC; Xiao BY; Lin GH; Wang C; Liu Q
    BMC Cancer; 2020 May; 20(1):393. PubMed ID: 32375701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.
    Hu T; Fang L; Shi L; Wang W; Huang Y
    Am J Otolaryngol; 2021; 42(5):102973. PubMed ID: 33812206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.
    Li T; Yang F; Ma K; Lv L
    Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma.
    Xu G; Wang Q; Wu X; Lv C; Zeng G; Xue Z; Cao R; Zhang N; Xiong W; Huang Q
    Technol Cancer Res Treat; 2021; 20():1533033821990017. PubMed ID: 33511908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
    Fang L; Shi L; Wang W; Hu T; Rao X
    Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.
    Wang P; Zhang M; Ke C; Cai C
    Medicine (Baltimore); 2020 Mar; 99(10):e19360. PubMed ID: 32150078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
    Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
    Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.
    Tang M; Jia Z; Zhang J
    Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.